Massimiliano Calabrese

Prof. Massimiliano Calabrese

Department of Neurosciences Biomedicine and Movements, The Multiple Sclerosis Center of the University Hospital of Verona, Verona, Veneto, Italy
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2009 in Archives of Neurology
Verified
Journal Article
Open access
PDF file
Massimiliano CalabreseMassimiliano Calabrese
Massimiliano Calabrese
FAFederica Agosta
Federica Agosta
FRFrancesca Rinaldi
Francesca Rinaldi
IMIrene Mattisi
Irene Mattisi
PGPaola Grossi
Paola Grossi
Massimo FilippiMassimo Filippi
Massimo Filippi
Cognitive impairment affects 40% to 65% of patients with multiple sclerosis (MS) and contributes significantly to their disability status.1,2 Although it is more frequent and severe in the progressive forms of MS, such an impairment can be present since the early clinical stages of the disease1,2 and typically includes deficits of long-term memory, attention and concentration, executive functioning, efficiency of information processing, and processing speed.1-4

20 February 2015 in Nature Reviews Neuroscience
Verified
Journal Article
Closed access
Massimiliano CalabreseMassimiliano Calabrese
Massimiliano Calabrese
RMRoberta Magliozzi
Roberta Magliozzi
OCOlga Ciccarelli
Olga Ciccarelli
JGJeroen J. G. Geurts
Jeroen J. G. Geurts
RRRichard Reynolds
Richard Reynolds
RMRoland Martin
Roland Martin

23 April 2018 in Annals of Neurology
Verified
Journal Article
Open access
PDF file
RMRoberta Magliozzi
Roberta Magliozzi
OHOwain Howell
Owain Howell
RNRichard Nicholas
Richard Nicholas
CCCarolina Cruciani
Carolina Cruciani
MCMarco Castellaro
Marco Castellaro
Massimiliano CalabreseMassimiliano Calabrese
Massimiliano Calabrese
Objective: Gray matter (GM) damage and meningeal inflammation have been associated with early disease onset and a more aggressive disease course in multiple sclerosis (MS), but can these changes be identified in the patient early in the disease course?Methods: To identify possible biomarkers linking meningeal inflammation, GM damage, and disease severity, gene and protein expression were analyzed in meninges and cerebrospinal fluid (CSF) from 27 postmortem secondary progressive MS and 14 control cases. Combined cytokine/chemokine CSF profiling and 3T magnetic resonance imaging (MRI) were performed at diagnosis in 2 independent cohorts of MS patients (35 and 38 subjects) and in 26 non‐MS patients.Results: Increased expression of proinflammatory cytokines (IFNγ, TNF, IL2, and IL22) and molecules related to sustained B‐cell activity and lymphoid‐neogenesis (CXCL13, CXCL10, LTα, IL6, and IL10) was detected in the meninges and CSF of postmortem MS cases with high levels of meningeal inflammation and GM demyelination. Similar proinflammatory patterns, including increased levels of CXCL13, TNF, IFNγ, CXCL12, IL6, IL8, and IL10, together with high levels of BAFF, APRIL, LIGHT, TWEAK, sTNFR1, sCD163, MMP2, and pentraxin III, were detected in the CSF of MS patients with higher levels of GM damage at diagnosis.Interpretation: A common pattern of intrathecal (meninges and CSF) inflammatory profile strongly correlates with increased cortical pathology, both at the time of diagnosis and at death. These results suggest a role for detailed CSF analysis combined with MRI as a prognostic marker for more aggressive MS. Ann Neurol 2018 Ann Neurol 2018;83:739–755

1 October 2012 in Brain
Verified
Journal Article
Closed access
PDF file
Massimiliano CalabreseMassimiliano Calabrese
Massimiliano Calabrese
VPValentina Poretto
Valentina Poretto
AFAlice Favaretto
Alice Favaretto
SASara Alessio
Sara Alessio
VBValentina Bernardi
Valentina Bernardi
PGPaolo Gallo
Paolo Gallo
Cortical inflammatory lesions have been correlated with disability and cortical atrophy in multiple sclerosis. The extent to which cortical lesion load is associated with longer-term physical and cognitive disability in different multiple sclerosis phenotypes has not yet been investigated. Thus, a 5-year prospective longitudinal study was carried on in a large group of patients with multiple sclerosis. Three hundred and twelve consecutive patients suffering from multiple sclerosis (157 relapsing remitting, 35 paediatric, 45 benign, 44 primary progressive and 31 secondary progressive) were enrolled in a 5-year prospective clinical and neuroimaging study. Several magnetic resonance parameters (including cortical lesion number and volume, contrast-enhancing cortical lesions and grey matter atrophy) were analysed to find associations with clinical and cognitive outcomes. Patients with high cortical lesion load had higher Expanded Disability Status Scale increase (median = 1.5; range = 0–3) during the study than both patients with low cortical lesion load (median = 1.0; range = 1–3, P < 0.001) and without cortical lesions (median = 0.5; range = −1 to 2, P < 0.001). Compared with clinically stable patients, 101 (32.4%) patients showing clinical progression at 5 years had the highest rate of cortical lesion accumulation (P < 0.001). Stepwise regression analysis revealed significant and independent contributions from age (β = 0.55), cortical lesion volume (β = 0.58), T2 white matter lesion volume (β = 0.34) and grey matter fraction (β = 0.42) as predictors (final model with r2 = 0.657, P < 0.001) of Expanded Disability Status Scale change. Disease duration (β = 0.52, P < 0.001), cortical lesion volume (β = 0.67, P < 0.001), grey matter fraction (β = 0.56, P < 0.001) and T2 white matter lesion volume (β = 0.31, P = 0.040) at baseline were found to be independent predictors of cognitive status at the end of the study. While confirming the relevance of cortical pathology in all multiple sclerosis phenotypes, but benign, our study suggests that grey matter and white matter changes in multiple sclerosis occur, at least, partly independently, and that grey matter, more than white matter, damage is associated with physical and cognitive disability progression. Thus, the combination of grey and white matter parameters gives a more comprehensive view of multiple sclerosis pathology and allows a better understanding of the progressive phase of the disease, which, however, seems more related to cortical damage than to subcortical white matter changes.

8 June 2010 in Neurology
Verified
Journal Article
Closed access
PDF file
NSN. De Stefano
N. De Stefano
AGA. Giorgio
A. Giorgio
MBM. Battaglini
M. Battaglini
MRMarco Rovaris
Marco Rovaris
MSM.P. Sormani
M.P. Sormani
Massimo FilippiMassimo Filippi
Massimo Filippi
Objective: To assess the time course of brain atrophy and the difference across clinical subtypes in multiple sclerosis (MS). Methods: The percent brain volume change (PBVC) was computed on existing longitudinal (2 time points) T1-weighted MRI from untreated (trial and nontrial) patients with MS. Patients (n = 963) were classified as clinically isolated syndromes suggestive of MS (CIS, 16%), relapsing-remitting (RR, 60%), secondary progressive (SP, 15%), and primary progressive (9%) MS. The median length of follow-up was 14 months (range 12–68). Results: There was marked heterogeneity of the annualized PBVC (PBVC/y) across MS subtypes (p = 0.003), with higher PBVC/y in SP than in CIS (p = 0.003). However, this heterogeneity disappeared when data were corrected for the baseline normalized brain volume. When the MS population was divided into trial and nontrial subjects, the heterogeneity of PBVC/y across MS subtypes was present only in the second group, due to the higher PBVC/y values found in trial data in CIS (p = 0.01) and RR (p < 0.001). The estimation of the sample sizes required for demonstrating a reduction of brain atrophy in patients in a placebo-controlled trial showed that this was larger in patients with early MS than in those with the progressive forms of the disease. Conclusions: This first large study in untreated patients with multiple sclerosis (MS) with different disease subtypes shows that brain atrophy proceeds relentlessly throughout the course of MS, with a rate that seems largely independent of the MS subtype, when adjusting for baseline brain volume.

1 February 2011 in Neurology
Verified
Journal Article
Closed access
PDF file
JGJ.J.G. Geurts
J.J.G. Geurts
SRS.D. Roosendaal
S.D. Roosendaal
Massimiliano CalabreseMassimiliano Calabrese
Massimiliano Calabrese
OCO. Ciccarelli
O. Ciccarelli
FAFederica Agosta
Federica Agosta
FBF. Barkhof
F. Barkhof
Background: Different double inversion recovery (DIR) sequences are currently used in multiple sclerosis (MS) research centers to visualize cortical lesions, making it difficult to compare published data. This study aimed to formulate consensus recommendations for scoring cortical lesions in patients with MS, using DIR images acquired in 6 European centers according to local protocols. Methods: Consensus recommendations were formulated and tested in a multinational meeting. Results: Cortical lesions were defined as focal abnormalities on DIR, hyperintense compared to adjacent normal-appearing gray matter, and were not scored unless ≥3 pixels in size, based on at least 1.0 mm2 in-plane resolution. Besides these 2 obligatory criteria, additional, supportive recommendations concerned a priori artifact definition on DIR, use of additional MRI contrasts to verify suspected lesions, and a constant level of displayed image contrast. Robustness of the recommendations was tested in a small dataset of available, heterogeneous DIR images, provided by the different participating centers. An overall moderate agreement was reached when using the proposed recommendations: more than half of the readers agreed on slightly more than half (54%) of the cortical lesions scored, whereas complete agreement was reached in 19.4% of the lesions (usually larger, mixed white matter/gray matter lesions). Conclusions: Although not designed as a formal interobserver study, the current study suggests that comparing available literature data on cortical lesions may be problematic, and increased consistency in acquisition protocols may improve scoring agreement. Sensitivity and specificity of the proposed recommendations should now be studied in a more formal, prospective, multicenter setting using similar DIR protocols.